Kodiak Sciences股價大漲145%,因Zenkuda和KSI-501在溼性AMD3期試驗中達成目標。這一後期試驗成功是Kodiak Sciences在溼性AMD領域的臨床里程碑。引述“Kodiak Sciences股價暴漲145%,因Zenkuda和KSI-501達成溼性AMD3期目標。”— Seekingalpha來源Kodiak Sciences skyrockets as Zenkuda, tabirafusp excel in late-stage wet AMD trialSeekingalpha